STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRAX
  4. [8-K] Praxis Precision Medicines, Inc. Reports Material Event

FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Praxis Precision Medicines reported that the FDA has extended by three months the review period for its New Drug Application for relutrigine, a treatment for SCN2A and SCN8A developmental and epileptic encephalopathies. The PDUFA target action date moved from September 27, 2026 to December 27, 2026.

The extension follows Praxis’s submission of additional sensitivity analyses of existing clinical data, which the FDA classified as a “major amendment,” requiring more review time. The agency did not request new clinical studies and did not raise safety or manufacturing concerns, and the review remains active. Praxis states it continues preparing for a potential relutrigine launch and remains confident in the strength of its application.

Positive

  • The FDA did not request new clinical studies and cited no safety or manufacturing concerns for relutrigine, indicating the existing data package remains under active review.
  • Praxis states it remains confident in the strength of the relutrigine application and continues commercial preparations for treating SCN2A and SCN8A developmental and epileptic encephalopathies.

Negative

  • The FDA extended the relutrigine NDA review period by three months, pushing the PDUFA target action date from September 27, 2026 to December 27, 2026, delaying potential approval and launch timing.

Insights

FDA extends relutrigine review by three months without new safety issues.

The FDA’s decision to extend review of relutrigine to December 27, 2026 reflects its need to evaluate additional sensitivity analyses deemed a “major amendment.” This is a timing setback but keeps the application under active review.

Importantly, the FDA did not request new clinical studies or cite safety or manufacturing concerns, suggesting current data remain under consideration rather than rejected. For a rare epilepsy program, a three‑month delay can affect launch timing but not necessarily ultimate approvability.

The key milestone is now the updated PDUFA target action date on December 27, 2026. Subsequent company communications and future filings will clarify whether any further information requests arise as the review progresses.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Original PDUFA date September 27, 2026 Initial FDA target action date for relutrigine NDA
New PDUFA date December 27, 2026 Updated FDA target action date after review extension
Review extension length Three months Additional time granted for FDA review of relutrigine NDA
New Drug Application regulatory
"the review period for its New Drug Application (“NDA”) for relutrigine"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
PDUFA target action date regulatory
"setting an updated PDUFA target action date from September 27, 2026 to December 27, 2026"
The PDUFA target action date is the deadline set by the U.S. Food and Drug Administration (FDA) by which it aims to decide whether to approve or reject a new drug application. This date helps investors gauge when a company’s new medication might reach the market, potentially influencing sales and revenue expectations. It acts as a key milestone signaling progress in the drug approval process.
developmental and epileptic encephalopathies medical
"for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (“DEEs”)"
Developmental and epileptic encephalopathies are a group of severe brain disorders that begin early in life, causing significant challenges with learning, development, and seizures. These conditions can limit a child's ability to grow and function normally, often requiring ongoing medical care. For investors, understanding these disorders highlights areas of medical research and treatment development that could lead to new therapies and market opportunities.
major amendment regulatory
"which the FDA has deemed a “major amendment,” allowing additional time for the FDA to review"
A major amendment is a significant change to an official company document, regulatory filing, contract, or planned offering that alters key terms, disclosures, financial commitments, or investor rights. Investors care because such changes can materially affect a company’s risk, valuation, or expected returns—like revising the rules of a game mid-play, requiring reassessment of whether the investment still fits their goals.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE000168954800016895482026-06-292026-06-29

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2026
PRAXIS PRECISION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39620
47-5195942
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Praxis Precision Medicines, Inc.
99 High Street, 30th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code)
(617) 300-8460
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 


Item 8.01. Other Events.
On June 29, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) notified the Company that it has extended by three months the review period for its New Drug Application (“NDA”) for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (“DEEs”), setting an updated PDUFA target action date from September 27, 2026 to December 27, 2026. The extension follows the Company’s submission of additional sensitivity analyses of existing clinical data, which the FDA has deemed a “major amendment,” allowing additional time for the FDA to review. No new clinical studies were requested, and the FDA did not cite any safety or manufacturing concerns. The review remains active and ongoing, and the Company is continuing its preparations to bring relutrigine to a patient community with significant unmet need. The Company remains confident in the strength of the relutrigine application and continues to collaborate with the FDA to support the completion of its review.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the anticipated timing of regulatory review and interactions and the commercial potential of the Company’s product candidates, including relutrigine. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, including, without limitation, uncertainties inherent in clinical trials and other risks as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PRAXIS PRECISION MEDICINES, INC.
Date: June 29, 2026By: /s/ Marcio Souza
 Marcio Souza
 Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Praxis Precision Medicines (PRAX) announce about the FDA review of relutrigine?

Praxis announced the FDA extended review of relutrigine’s NDA by three months. The PDUFA target action date moved from 27 September 2026 to 27 December 2026 after the company submitted additional sensitivity analyses.

Why did the FDA extend Praxis Precision Medicines’ relutrigine PDUFA date?

The FDA extended the PDUFA date because Praxis submitted additional sensitivity analyses of existing clinical data. The agency deemed this a “major amendment,” which automatically allows extra time for a more complete review of the New Drug Application.

Did the FDA raise any safety or manufacturing concerns about PRAX’s relutrigine?

No, the FDA did not cite safety or manufacturing concerns for relutrigine. The agency also did not request new clinical studies, indicating its focus is on reviewing the additional sensitivity analyses within the existing data package.

What condition is Praxis’s relutrigine being reviewed to treat?

Relutrigine is being reviewed to treat SCN2A and SCN8A developmental and epileptic encephalopathies. These are severe genetic epilepsies, and Praxis highlights a significant unmet medical need in this patient community for effective, targeted therapies.

What is the new PDUFA target action date for Praxis’s relutrigine NDA?

The new PDUFA target action date is 27 December 2026. This replaces the prior 27 September 2026 date, following the FDA’s decision to treat Praxis’s additional sensitivity analyses as a major amendment requiring extra review time.

Filing Exhibits & Attachments

3 documents

Other Documents